Back to Directory
Last Updated: 09/06/2026
DJS Antibodies
Oxford
Founded 2014
Antibody discovery biotech targeting GPCRs in inflammatory disease
DJS Antibodies is a biotechnology company developing monoclonal antibody therapeutics against G protein-coupled receptors and other previously intractable disease targets.
Its proprietary antibody discovery platform enables the generation of first-in-class antibodies against transmembrane proteins that have historically resisted biologics approaches.
The lead programme targets a receptor implicated in idiopathic pulmonary fibrosis and other fibrotic diseases.
DJS Antibodies was acquired by AbbVie in 2022 and continues to operate from its Oxford research facility.